Clinical trials: Gastro-intestinal Stromal Tumors
Gastrointestinal Stromal Tumors
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be studied in these patients.
- Trial name
- NCT01396148
- Testing
- sunitinib malate dose escalation, sunitinib malate
- Where
- 9 sites in United States, Czechia and 1 more
- Volunteers
- 6 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
KIT exon 9 mutants had poorer survival compared with KIT exon 11 mutants when they were treated with the same dose of imatinib, 400 mg per day, and that patients with KIT exon 9 mutation had better progression-free survival with…
- Trial name
- NCT01541709
- Testing
- imatinib
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumors
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
The purpose of this study is to collect and assess long-term safety of nilotinib in patients who are on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs study and are benefiting from…
- Trial name
- NCT01863745
- Testing
- nilotinib
- Where
- 11 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Hand-Foot Skin Reaction (HFSR)
ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction
This study aims to evaluate whether a combination of oral zinc supplementation and transdermal clobetasol cream is effective in preventing and reducing the severity of hand-foot skin reaction (HFSR) induced by regorafenib…
- Trial name
- ZINCLO-HAND (NCT06856590)
- Testing
- Zinc Supplementation, Clobetasol Propionate 0.05% Cream
- Where
- 13 sites in Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Gazi University
Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors
Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects
The purpose of this study is to evaluate safety and tolerance by comparing pharmacokinetic characteristics between the Luckyvec 400mg tablet(x 1T) and Glivec 100mg(x 4T) when administered a single-dose to healthy volunteers.
- Trial name
- Imatinib (NCT01270984)
- Testing
- Luckyvec 400mg film coated tablet, Glivec 100mg film coated tablet
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Gastrointestinal Neoplasms
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug…
- Trial name
- NCT07218926
- Testing
- IDRX-42, Sunitinib
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline
Gastrointestinal Stromal Tumors
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Multicenter, open-label Phase 1b/2 study of ripretinib in combination with binimetinib in patients with gastrointestinal stromal tumor (GIST).
- Trial name
- NCT05080621
- Testing
- Ripretinib, binimetinib
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors
Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)
This study will evaluate the efficacy, safety, tolerability of imatinib in the neoadjuvant treatment (pre-operatory) of patients with GIST.
- Trial name
- CONVERT (NCT01483014)
- Testing
- imatinib mesylate
- Where
- 11 sites in Brazil
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
GIST and CML
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
This Phase IV, open-label, multicenter roll-over study evaluated the long-term safety of imatinib in patients who had completed a previous Novartis-sponsored imatinib study and were considered by the investigator to continue…
- Trial name
- NCT01742299
- Testing
- imatinib mesylate
- Where
- 29 sites in United States, China and 9 more
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Stromal Tumor, Major Gastrectomy
Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy
The most common sites for GIST to occur are the stomach (60-70%) and proximal small intestines (20-25%). Therefore patients with GIST often have altered GI-tract due to tumor resection or palliative surgery which might affect…
- Trial name
- ABILITY (NCT02185937)
- Testing
- cola
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Radboud University Medical Center
Gastrointestinal Stromal Tumors (GISTs)
A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Recent preclinical study has suggested a potential possibility that imatinib might promote tumor growth in the presence of secondary resistance mutations [10].
- Trial name
- NCT02712112
- Testing
- Imatinib Mesylate
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Asan Medical Center
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumors
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
To monitor use in real practice including adverse events and efficacy on Sutent capsules (Sunitinib malate)
- Trial name
- NCT00444795
- Testing
- Sunitinib malate
- Where
- 47 sites in South Korea
- Volunteers
- 520 people
- Sponsor
- Pfizer
Gastrointestinal Neoplasm
Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial
The purpose of this study is to determine the genetic makeup of gastro intestinal stomach tumors (GISTs) from patients enrolled in the A6181112 phase IIIb trial.
- Trial name
- NCT00640692
- Sponsor
- Oregon Health and Science University
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumor, Sarcoma
SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas
Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced, metastatic, or recurrent soft tissue sarcomas. SU5416 may stop the growth of soft tissue sarcomas by stopping blood flow to the tumor.
- Trial name
- NCT00005862
- Testing
- semaxanib
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumors
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
To evaluate the antitumor activity of SU011248 in advanced, imatinib mesylate-resistant gastrointestinal stromal tumor (GIST) when administered on a continuous daily dosing schedule
- Trial name
- NCT00137449
- Testing
- SU011248
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 60 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumor
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving imatinib mesylate before surgery may shrink the tumor so that it can be removed.
- Trial name
- NCT00112632
- Testing
- imatinib mesylate, conventional surgery, neoadjuvant therapy
- Where
- 9 sites in Austria, Germany
- Volunteers
- 40 people
- Sponsor
- Technical University of Munich
Gastrointestinal Stromal Tumor
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
This randomized phase III trial studies imatinib mesylate and bevacizumab to see how well they work compared to imatinib mesylate alone in treating patients with gastrointestinal stromal tumor that has spread to other parts of…
- Trial name
- S0502 (NCT00324987)
- Testing
- Bevacizumab, Imatinib Mesylate, Laboratory Biomarker Analysis
- Where
- 192 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)